Four years ago, Xeris Biopharma was losing more than two dollars for every dollar it brought in. Today, the 10-K for fiscal year 2025 shows the company crossed into the black for the first time. That is not a rounding error. It is the end of a long, expensive climb, and the market has noticed: the stock has gained sharply over the past six months, our data show. The question worth sitting with is whether the price now reflects the climb already completed, or the one still ahead.
The story, briefly
Xeris spent years burning cash to build a commercial base; the filed numbers show it finally stopped losing money in 2025. The stock has repriced sharply to match that milestone. But the price-to-sales ratio, our data show, sits near the 87th percentile of the company’s own history, meaning the market is paying a premium it has rarely paid before. The open question is whether the next leg of growth, anchored to a pipeline drug that won’t read out until late 2028, justifies a valuation built for a company that has already arrived.
How it got here
Xeris built its commercial foundation on two emergency glucagon products: Gvoke, a ready-to-use liquid injection for severe low blood sugar, and Ogluo, an autoinjector version sold in Europe. In the early years, the company was still tiny, with losses that dwarfed its sales. Then it acquired Recorlev, a treatment for Cushing’s syndrome, a rare hormonal disorder, and revenue roughly doubled in a single year. By the full-year 2025 filing, revenue had reached $292 million, growing 44% in a year, and the net loss had shrunk to essentially nothing.
That trajectory matters because it was not accidental. The company layered products onto a shared commercial infrastructure, spreading fixed costs across a growing revenue base until the math finally worked. A business that once needed more than a dollar of spending to generate a dollar of sales now keeps a thin sliver of each dollar as profit. Thin is not the same as fragile, but it is not a cushion either.
What the most recent quarter shows
The latest filed quarter, ended June 30, 2026, reported in the Q2 2026 10-Q, shows net product revenue up 34% from a year earlier, crossing $91 million for the quarter. That is a strong number. The complication sits inside it: Gvoke, the product that started this company’s commercial story, posted a modest year-over-year decline in the same period, per the Q2 2026 earnings release. One flagship product slipping while the total grows means Recorlev is carrying more of the load. That concentration is worth watching.
The Q2 2026 earnings release shows management tightened its full-year 2026 revenue guidance to a range implying roughly a third more revenue than 2025. If it holds, that would be the company’s second consecutive year of accelerating growth after years of deceleration. Q3 2026 results are scheduled for November 5, 2026; that filing will be the next material update to the revenue trajectory described here.
The bet behind the valuation
The governance news from November 2, 2026, a board expansion 8-K, is not the story. Adding a director and granting a routine equity award is housekeeping. The real story is what the board is being asked to oversee.
Xeris’s pipeline centers on XP-8121, a once-weekly injectable form of levothyroxine, the standard thyroid hormone replacement taken daily by tens of millions of people worldwide. The pitch is simple: same drug, one shot a week instead of a pill every morning. The company’s pivotal “Cornerstone” trial is expected to start by the end of 2026, per the company’s pipeline update, with top-line results not expected until late 2028 and a potential launch around 2030. Management has cited a peak revenue opportunity in the billions for XP-8121, though that range spans an enormous amount of uncertainty and the trial has not yet started.
That four-year runway to a data readout is the central fact in any assessment of whether the current valuation is justified by the pipeline. The current valuation, our data show, puts the price-to-sales ratio at nearly 7 times, against a historical median closer to 4.5 times. The market is paying, in other words, for a story that includes XP-8121 succeeding. Phase 3 trials in this space do not always oblige.
Reading the numbers
- Net margin, FY2025: 0.2%. What it is: the share of each revenue dollar left after all costs. What it means here: Xeris crossed from loss-making to profitable for the first time, but just barely. In everyday terms, a shop that takes in $1,000 and keeps $2 is profitable, but one bad month erases it. Filed in the FY2025 10-K.
- Revenue growth, FY2025: 44%. What it is: how much faster sales grew than the prior year. What it means here: Xeris grew roughly ten times faster than the broader U.S. economy last year. A business growing that fast is either taking share, adding products, or both. Filed in the FY2025 10-K.
- Q2 2026 net product revenue: $91 million, up 34%. What it is: sales of approved drugs in a single quarter. What it means here: annualized, this quarter alone would nearly match all of FY2023. Filed in the Q2 2026 10-Q.
- Price-to-sales ratio: 6.7 times, 87th percentile of own history. What it is: the price tag per dollar of annual sales, a multiple (the amount investors pay per dollar of revenue). What it means here: a family paying $6.70 for every $1 of groceries in the basket, when they normally pay $4.50. Our data, computed from SEC filings and market prices.
Sources
- 10-Q, quarter ended June 30, 2026
- 10-K, fiscal year ended December 31, 2025
- 8-K filed November 2, 2026, via Stock Titan
- Xeris Q2 2026 earnings release
- Xeris pipeline update, XP-8121
